Bezlotoxumab Associated With Decreased Risk For Recurrent CDI Among Transplant Recipients, Study Finds
July 08, 2021
Infectious Disease Advisor (7/7, Nye) reports, “Bezlotoxumab was found to be associated with decreased risk for recurrent Clostridioides difficile infection (CDI) among patients having undergone solid organ or hematopoietic cell transplantation,” research...